Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / DAFNA Capital Management LLC
Form 13F · Q2 2026

DAFNA Capital Management LLC

CIK 1389933Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$524M
Reported book value
88
Positions
12
Quarters on record
Top 50
Positions

DAFNA Capital Management LLC — holdings

Top 50 positions of 88, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1RVMD Revolution Medicines Inc562,630−3.1%$105M20.1%
2SPDR SERIES TRUST Spdr Series Trust196,505−38.3%$31M5.9%
3CMPS Compass Pathways Plc2.0M−16.8%$28M5.4%
4STXS Stereotaxis Inc13.7M+0.0%$24M4.5%
5NKTR Nektar Therapeutics318,380+92.7%$22M4.2%
6DNLI Denali Therapeutics Inc739,014+132.0%$19M3.6%
7IDYA Ideaya Biosciences Inc497,240+4.3%$19M3.5%
8ATRC Atricure Inc597,431+0.0%$17M3.2%
9XENE Xenon Pharmaceuticals Inc250,772+0.0%$15M2.9%
10CYTK Cytokinetics Inc171,998−20.9%$15M2.8%
11RCUS Arcus Biosciences Inc441,829−0.5%$14M2.6%
12ASND Ascendis Pharma A/S48,469—$13M2.5%
13NBIX Neurocrine Biosciences Inc57,769−18.2%$10M1.9%
14AXGN Axogen Inc208,960−16.4%$10M1.8%
15PODD Insulet Corp61,870+469.2%$9M1.8%
16EWTX Edgewise Therapeutics Inc226,819+102.1%$9M1.8%
17BCAX Bicara Therapeutics Inc284,955−32.4%$8M1.6%
18ISHARES TR Ishares Tr42,595−31.4%$8M1.5%
19SNDX Syndax Pharmaceuticals Inc335,255+54.2%$7M1.4%
20MPLT Maplight Therapeutics Inc171,006+0.0%$6M1.2%
21LRMR Larimar Therapeutics Inc2.0M−1.0%$6M1.2%
22IPSC Century Therapeutics Inc2.4M−1.4%$6M1.1%
23DXCM Dexcom Inc86,279+0.0%$6M1.1%
24IMVT Immunovant Inc149,524−0.7%$6M1.1%
25INGN Inogen Inc845,179+0.0%$5M1.0%
26TNDM Tandem Diabetes Care Inc355,208+0.0%$5M1.0%
27ALKS Alkermes Plc101,266−27.4%$5M1.0%
28STOK Stoke Therapeutics Inc130,875+0.0%$4M0.8%
29ALLO Allogene Therapeutics Inc2.0M+46.0%$4M0.8%
30BCRX Biocryst Pharmaceuticals Inc400,248−7.0%$4M0.8%
31LKFT Lakefront Biotherapeutics130,175+0.0%$4M0.7%
32KIDS Orthopediatrics Corp189,130+97.7%$4M0.7%
33CYBIN INC Cybin Inc514,061+3.2%$3M0.6%
34RAPP Rapport Therapeutics Inc75,000+0.0%$3M0.6%
35KYMR Kymera Therapeutics Inc27,000—$3M0.6%
36PROQR THRAPEUTICS N V Proqr Thrapeutics N V1.5M−2.4%$3M0.5%
37NGNE Neurogene Inc89,032+57.2%$3M0.5%
38ANL Adlai Nortye Ltd239,553—$3M0.5%
39PRCT Procept Biorobotics Corp120,000+0.0%$3M0.5%
40AQST Aquestive Therapeutics Inc645,915+75.3%$3M0.5%
41CLDX Celldex Therapeutics Inc New68,518+0.0%$3M0.5%
42GPCR Structure Therapeutics Inc46,500+0.0%$2M0.5%
43ALGN Align Technology Inc14,000−6.7%$2M0.5%
44VKTX Viking Therapeutics Inc59,516+0.0%$2M0.4%
45NGEN Nervgen Pharma Corp1.1M—$2M0.4%
46BHVN Biohaven Ltd137,593−83.7%$2M0.4%
47MAZE Maze Therapeutics Inc65,000+85.7%$2M0.4%
48ALEC Alector Inc908,351+0.0%$2M0.3%
49LXEO Lexeo Therapeutics Inc377,059+0.0%$2M0.3%
50PROF Profound Med Corp260,360−1.0%$2M0.3%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.